Science

Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial

Shilpa Gupta/X

Apr 2, 2025, 11:04

Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial

ESMO Open shared the post on X:

“Exploratory analysis on elderly (>65yrs) patients enrolled in JAVELINBladder100 trial in ESMO Open.

Efficacy & tolerability of maintenance avelumab confirmed with increased quality-adjusted time w/o symptoms/toxicity.”

Shilpa Gupta, Director of Genitourinary Oncology, a staff member in Hematology and Oncology and a Professor of Medicine at Cleveland Clinic, reshared the post on X, adding:

“Happy to share our exploratory analysis on safety & tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial.

No new safety signals, efficacy well maintained in this subgroup.

Avelumab 1L maintenance prolonged OS versus BSC alone Quality-adjusted time without symptoms or toxicity was 4.57 months longer with avelumab versus BSC alone.”

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patients.

Authors: Shilpa Gupta, et al.

Shilpa Gupta: Safety and tolerability of maintenance avelumab in elderly patients subgroup from Javelin Bladder 100 trial

Avelumab cancer Cleveland Clinic ESMO Open fight against cancer Genitourinary Oncology Global fight against cancer Javelin Bladder JAVELINBladder100 OncoDaily Oncology Shilpa Gupta urothelial carcinoma

Where to Study to Become ASCO President: 2025 Institutional Rankings

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

Dr. Don Dizon and Dr. Nathan Pennell Reflect on the Evolution of the ASCO Educational Book

April is Head and Neck Cancer Awareness Month